{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:12:10Z","timestamp":1789924330872,"version":"4.0.1"},"reference-count":32,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/objective:<\/jats:title>\n                    <jats:p>Observational clinical data from cladribine-treated patients with relapsing forms of multiple sclerosis (MS) were recorded in the Australian MS registry powered by the MSBase registry platform (5-year follow-up) and analysed to complement information from the pivotal cladribine clinical trials in MS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A cohort of 90 cladribine-treated patients with follow-up data reported by treating physicians and recorded in the Australian MSBase registry (database lock February 2016) were examined. Clinical data included Expanded Disability Status Scale (EDSS) scores, relapses and other disease-modifying drugs (DMDs) administered before and after cladribine treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Mean age on starting cladribine was 47\u2009years; mean age at MS onset was 34\u2009years, and median baseline EDSS score was 5.25. Disability trajectories in patients with sufficient follow-up suggested an overall increasing trend prior to cladribine treatment which was reduced during the 2-year post-treatment. Approximately 80% of patients were EDSS progression-free, 65% remained relapse-free after 2\u2009years and median time to next DMD was 1.7\u2009years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These observational data suggest a disease-modifying effect in this cohort of relapsing MS patients characterised by older and more disabled patients. Since these data represent a single-arm cohort, clinical trials and larger comparative post-marketing studies are needed to validate and extend these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1352458520921087","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T11:29:51Z","timestamp":1591961391000},"page":"465-474","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":45,"title":["Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy"],"prefix":"10.1177","volume":"27","author":[{"given":"Nathaniel","family":"Lizak","sequence":"first","affiliation":[{"name":"CORe, Department of Medicine, University of Melbourne, Melbourne, VIC, Australia\/The Alfred Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hodgkinson","sequence":"additional","affiliation":[{"name":"Ingham Institute for Applied Medical Research, UNSW Medicine, Liverpool, NSW, Australia\/Liverpool Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Butler","sequence":"additional","affiliation":[{"name":"Monash Medical Centre, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[{"name":"Hunter New England Health and Hunter Medical Research Institute, University of Newcastle, Callaghan, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Slee","sequence":"additional","affiliation":[{"name":"Flinders University, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela Ann","family":"McCombe","sequence":"additional","affiliation":[{"name":"Royal Brisbane and Women\u2019s Hospital, University of Queensland, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Shaw","sequence":"additional","affiliation":[{"name":"Geelong Hospital, Geelong, VIC, Australia\/Deakin University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Skibina","sequence":"additional","affiliation":[{"name":"The Alfred Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Vucic","sequence":"additional","affiliation":[{"name":"Westmead Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Shuey","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H","family":"Barnett","sequence":"additional","affiliation":[{"name":"Brain and Mind Centre, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Parratt","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[{"name":"Central Clinical School, Monash University, Melbourne, VIC, Australia\/Eastern Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Jack","sequence":"additional","affiliation":[{"name":"Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Fabris","sequence":"additional","affiliation":[{"name":"Merck Serono Australia Pty Ltd, Frenchs Forest, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[{"name":"CORe, Department of Medicine, University of Melbourne, Melbourne, VIC, Australia\/Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"bibr1-1352458520921087","unstructured":"Merck Serono Australia Pty Ltd. Product information, MAVENCLAD tablets. Frenchs Forest, NSW, Australia: Merck Serono Australia, 2017. Available at: www.tga.gov.au."},{"key":"bibr2-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"bibr3-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6775-0"},{"key":"bibr4-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603"},{"key":"bibr5-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1177\/2055217317732802"},{"key":"bibr6-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70005-5"},{"key":"bibr7-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2011.08.006"},{"key":"bibr8-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518771875"},{"key":"bibr9-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000477"},{"key":"bibr10-1352458520921087","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2017.076"},{"key":"bibr11-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517728812"},{"key":"bibr12-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1177\/1352458506070775"},{"key":"bibr13-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22366"},{"key":"bibr14-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514521517"},{"key":"bibr15-1352458520921087","first-page":"2395","volume":"139","author":"Lorscheider J","year":"2016","journal-title":"J Neurol"},{"key":"bibr16-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516653667"},{"key":"bibr17-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516662728"},{"key":"bibr18-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1177\/2055217316666406"},{"key":"bibr19-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7862-9"},{"key":"bibr20-1352458520921087","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1212\/WNL.90.15_supplement.S47.004","volume":"90","author":"Weideman AM","year":"2018","journal-title":"Neurology"},{"key":"bibr21-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv258"},{"key":"bibr22-1352458520921087","doi-asserted-by":"crossref","unstructured":"Schippling S, Sormani MP, De Stefano N, et al. CLARITY: An analysis of severity and frequency of relapses in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets or placebo, 2018, https:\/\/onlinelibrary.ectrims-congress.eu\/ectrims\/2018\/ectrims-2018\/228393\/sven.schippling.clarity.an.analysis.of.severity.and.frequency.of.relapses.in.html","DOI":"10.26226\/morressier.5b75785f5aff7400151f3bdc"},{"key":"bibr23-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70023-0"},{"key":"bibr24-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0693-y"},{"key":"bibr25-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.01.042"},{"key":"bibr26-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8830-y"},{"key":"bibr27-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.02.018"},{"key":"bibr28-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419836913"},{"key":"bibr29-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419854986"},{"key":"bibr30-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617753365"},{"key":"bibr31-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.11.021"},{"key":"bibr32-1352458520921087","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.11.001"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458520921087","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1352458520921087","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458520921087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:03:12Z","timestamp":1777694592000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458520921087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1177\/1352458520921087"],"URL":"https:\/\/doi.org\/10.1177\/1352458520921087","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]}}}